Cheng Peng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Cheng Peng has a total of 67 co-authors. Here are the top co-authors by number of shared publications:
- Yunxia Li
State Key Laboratory of Southwestern Chinese Medicine Resources, School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, 611137, China
23 shared publications Lihong Gong
State Key Laboratory of Southwestern Chinese Medicine Resources, Key Laboratory of Standardization for Chinese Herbal Medicine, Ministry of Education, School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China
14 shared publicationsCheng Wang
State Key Laboratory of Southwestern Chinese Medicine Resources, Key Laboratory of Standardization for Chinese Herbal Medicine, Ministry of Education, School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China
13 shared publicationsYan Li
Pharmacy College, Chengdu University of Traditional Chinese Medicine, No.1166, Liutai Avenue; The Ministry of Education Key Laboratory of Standardization of Chinese Herbal Medicine; State Key Laboratory Breeding Base of Systematic Research, Development and Utilization of Chinese Medicine Resource, Chengdu, 610075, People's Republic of China
7 shared publicationsXiao-Hong Gong
State Key Laboratory Breeding Base of Systematic Research, Development and Utilization of Chinese Medicine Resources, Pharmacy College, Chengdu University of Traditional Chinese Medicine, Chengdu, China
6 shared publicationsXuyang Dai
State Key Laboratory of Southwestern Chinese Medicine Resources, Key Laboratory of Standardization for Chinese Herbal Medicine, Ministry of Education, School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, 611137, China
6 shared publications
Latest Publications
- Open Access
- 4 September 2023
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 166, 115410
A comprehensive review on pharmacological, toxicity, and pharmacokinetic properties of phillygenin: Current landscape and future perspectives
- 4 September 2023
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 166, 115410
Open AccessA comprehensive review on pharmacological, toxicity, and pharmacokinetic properties of phillygenin: Current landscape and future perspectives
- Top Cited PapersOpen Access
- 15 May 2023
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 163, 114882
Celastrol as an emerging anticancer agent: Current status, challenges and therapeutic strategies
- 15 May 2023
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 163, 114882
Top Cited PapersOpen AccessCelastrol as an emerging anticancer agent: Current status, challenges and therapeutic strategies
- Open Access
- 30 November 2022
- Published by Elsevier in Pharmacological Research
- Vol. 187, 106587
Cucurbitacin B: A review of its pharmacology, toxicity, and pharmacokinetics
- 30 November 2022
- Published by Elsevier in Pharmacological Research
- Vol. 187, 106587
Open AccessCucurbitacin B: A review of its pharmacology, toxicity, and pharmacokinetics
- Open Access
- 21 November 2022
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 157, 114040
Mesenchymal stem cell-derived exosomes and non-coding RNAs: Regulatory and therapeutic role in liver diseases
- 21 November 2022
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 157, 114040
Open AccessMesenchymal stem cell-derived exosomes and non-coding RNAs: Regulatory and therapeutic role in liver diseases
- 1 October 2021
- Published by Elsevier in Toxicology Letters
- Vol. 351, 37-52
The dual role of immune response in acetaminophen hepatotoxicity: Implication for immune pharmacological targets
- 1 October 2021
- Published by Elsevier in Toxicology Letters
- Vol. 351, 37-52
The dual role of immune response in acetaminophen hepatotoxicity: Implication for immune pharmacological targets
- 1 October 2021
- Published by Elsevier in Phytomedicine
- Vol. 91, 153694
Hydroxysafflor yellow A, a natural compound from Carthamus tinctorius L with good effect of alleviating atherosclerosis
- 1 October 2021
- Published by Elsevier in Phytomedicine
- Vol. 91, 153694
Hydroxysafflor yellow A, a natural compound from Carthamus tinctorius L with good effect of alleviating atherosclerosis
- 1 July 2021
- Published by Elsevier in Pharmacological Research
- Vol. 169, 105690
A review of pharmacological and pharmacokinetic properties of Forsythiaside A
- 1 July 2021
- Published by Elsevier in Pharmacological Research
- Vol. 169, 105690
A review of pharmacological and pharmacokinetic properties of Forsythiaside A
- 22 June 2021
- Published by Wiley in Phytotherapy Research
- Vol. 35 (9) , 4727-4747
Quercetin as a protective agent for liver diseases: A comprehensive descriptive review of the molecular mechanism
Quercetin is the major representative of the flavonoid subgroup of flavones, with good pharmacological activities for the treatment of liver diseases, including liver steatosis, fatty hepatitis, liver fibrosis, and liver cancer. It can significantly influence the development of liver diseases via multiple targets and multiple pathways via antifat accumulation, anti‐inflammatory, and antioxidant activity, as well as the inhibition of cellular apoptosis and proliferation. Despite extensive research on understanding the mechanism of quercetin in the treatment of liver diseases, there are still no targeted therapies available. Thus, we have comprehensively searched and summarized the different targets of quercetin in different stages of liver diseases and concluded that quercetin inhibited inflammation of the liver mainly through NF‐κB/TLR/NLRP3, reduced PI3K/Nrf2‐mediated oxidative stress, mTOR activation in autophagy, and inhibited the expression of apoptotic factors associated with the development of liver diseases. In addition, quercetin showed different mechanisms of action at different stages of liver diseases, including the regulation of PPAR, UCP, and PLIN2‐related factors via brown fat activation in liver steatosis. The compound inhibited stromal ECM deposition at the liver fibrosis stage, affecting TGF1β, endoplasmic reticulum stress (ERs), and apoptosis. While at the final liver cancer stage, inhibiting cancer cell proliferation and spread via the hTERT, MEK1/ERK1/2, Notch, and Wnt/β‐catenin‐related signaling pathways. In conclusion, quercetin is an effective liver protectant. We hope to explore the pathogenesis of quercetin in different stages of liver diseases through the review, so as to provide more accurate targets and theoretical basis for further research of quercetin in the treatment of liver diseases.
- 22 June 2021
- Published by Wiley in Phytotherapy Research
- Vol. 35 (9) , 4727-4747
Quercetin as a protective agent for liver diseases: A comprehensive descriptive review of the molecular mechanism
Quercetin is the major representative of the flavonoid subgroup of flavones, with good pharmacological activities for the treatment of liver diseases, including liver steatosis, fatty hepatitis, liver fibrosis, and liver cancer. It can significantly influence the development of liver diseases via multiple targets and multiple pathways via antifat accumulation, anti‐inflammatory, and antioxidant activity, as well as the inhibition of cellular apoptosis and proliferation. Despite extensive research on understanding the mechanism of quercetin in the treatment of liver diseases, there are still no targeted therapies available. Thus, we have comprehensively searched and summarized the different targets of quercetin in different stages of liver diseases and concluded that quercetin inhibited inflammation of the liver mainly through NF‐κB/TLR/NLRP3, reduced PI3K/Nrf2‐mediated oxidative stress, mTOR activation in autophagy, and inhibited the expression of apoptotic factors associated with the development of liver diseases. In addition, quercetin showed different mechanisms of action at different stages of liver diseases, including the regulation of PPAR, UCP, and PLIN2‐related factors via brown fat activation in liver steatosis. The compound inhibited stromal ECM deposition at the liver fibrosis stage, affecting TGF1β, endoplasmic reticulum stress (ERs), and apoptosis. While at the final liver cancer stage, inhibiting cancer cell proliferation and spread via the hTERT, MEK1/ERK1/2, Notch, and Wnt/β‐catenin‐related signaling pathways. In conclusion, quercetin is an effective liver protectant. We hope to explore the pathogenesis of quercetin in different stages of liver diseases through the review, so as to provide more accurate targets and theoretical basis for further research of quercetin in the treatment of liver diseases.